Safety and Efficacy Clinical Trials for SYL1001, a Novel Short Interfering RNA for the Treatment of Dry Eye Disease | Zendy

J.M. Benítez-del-Castillo | Zendy; Javier MorenoMontañés | Zendy; Ignacio Jiménez-Alfaro | Zendy; Francisco J. MuñozNegrete | Zendy; Krista Turman | Zendy; Kadi Palumaa | Zendy; Belén Sádaba | Zendy; Marı́a Victoria González | Zendy; Verónica Ruz | Zendy; Beatriz Vargas | Zendy; Covadonga Pañeda | Zendy; Tamara Martı́nez | Zendy; Anne-Marie Bleau | Zendy; Ana Isabel Jiménez | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Safety and Efficacy Clinical Trials for SYL1001, a Novel Short Interfering RNA for the Treatment of Dry Eye Disease

Author(s) -

J.M. Benítez-del-Castillo,

Javier MorenoMontañés,

Ignacio Jiménez-Alfaro,

Francisco J. MuñozNegrete,

Krista Turman,

Kadi Palumaa,

Belén Sádaba,

Marı́a Victoria González,

Verónica Ruz,

Beatriz Vargas,

Covadonga Pañeda,

Tamara Martı́nez,

Anne-Marie Bleau,

Ana Isabel Jiménez

Publication year - 2016

Publication title -

investigative ophthalmology and visual science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.935

H-Index - 218

eISSN - 1552-5783

pISSN - 0146-0404

DOI - 10.1167/iovs.16-20303

Subject(s) - medicine , tolerability , placebo , clinical trial , visual analogue scale , adverse effect , clinical endpoint , therapeutic effect , ophthalmology , gastroenterology , surgery , pathology , alternative medicine

To evaluate the efficacy and safety of SYL1001, a short interfering (si) RNA targeting the transient receptor potential cation channel subfamily V member 1 (TRPV1), for the treatment of dry eye disease (DED).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research